Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    PRAN-16-52
Previous Study | Return to List | Next Study

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03151408
Recruitment Status : Terminated (The IDMC recommended to stop the study prematurely due to a lack of efficacy.)
First Posted : May 12, 2017
Last Update Posted : September 9, 2020
Sponsor:
Collaborator:
Clinipace Worldwide
Information provided by (Responsible Party):
Helsinn Healthcare SA

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Terminated
Actual Primary Completion Date : August 20, 2020
Actual Study Completion Date : August 20, 2020
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 August 20, 2021
September 15, 2021 Submission with QC Comments
2 September 28, 2021
October 27, 2021 Submission with QC Comments
3 November 4, 2021
December 2, 2021 Submission with QC Comments
4 December 15, 2021
January 12, 2022 Submission with QC Comments